11 th National Conference on Laboratory Aspects of Tuberculosis, April 23 rd 2019 Frances Jamieson, MD FRCPC Medical Lead, TB and Mycobacteriology Laboratory, Public Health Ontario
11th National Conference on Laboratory Aspects of Tuberculosis, April 23rd 2019
Frances Jamieson, MD FRCPC
Medical Lead, TB and Mycobacteriology Laboratory, Public Health Ontario
PublicHealthOntario.ca
Declaration of Conflict of Interest
• I have no conflicts to declare
PublicHealthOntario.ca
Outline and objectives
1. Overview of TB and Mycobacteriology laboratory, Public Health Ontario and mycobacteria epidemiology in Ontario
2. General review of MALDI-ToF technology and application in PHO laboratories
3. Evaluation: MALDI-ToF extraction method development, and MALDI-ToFvalidation
4. Evolution: MALDI-ToF implementation and experience, interesting observations and lessons learned
PublicHealthOntario.ca
TB and Mycobacteriology Labs in Ontario
Timmins
Ottawa
TORONTO
London
Public Health Ontario Lab Network
PHL-Toronto and 3 Regional PHLs
Ottawa Hospital
Dynacare (community lab)
PublicHealthOntario.ca
TB @PHOL: By the Numbers…
• Largest TB and Mycobacteriology laboratory in North America (by volume) - avg. 65,000 specimens processed annually (56,000 in Toronto)
• Provide >95% of diagnostic testing and 100% of reference testing for Ontario
• Over 200 AFB smears are read daily (one primary reader and one secondary) – Toronto lab
• Over 200 culture positive specimens and referred cultures identified weekly – Toronto lab
PublicHealthOntario.ca 6
0
2000
4000
6000
8000
10000
12000
20
00
20
01
20
02
20
03
20
04
20
05
20
06
20
07
20
08
20
09
20
10
20
11
20
12
20
13
20
14
20
15
20
16
20
17
Nu
mb
er
Year
Total positive
NTM
TB
Proportion of MtbC and NTM Isolated-PHL Toronto
PublicHealthOntario.ca 7
14.7%
63.0%
5.4%
10.7%
5.7%
0.5%
% Mycobacteria spp. 2017 (n=11,919)
Mtb
MAC (M. avium and M.intracellulare)**
M. xenopi
Common Rapid growers(non-pigmented)*
Other NTM
M. kansasii
*M. fortuitum, M. chelonae, M. abscessus group, M. peregrinum, M. mucogenicum, M. senegalense
**M. avium 90.7% and M. intracellulare 8.5% of MAC isolates
8
Incubate
up to 7
wks
Smear Culture
TB DST;
report in
8-10 days
New smear
positive, smear
negative on
request
Daily
TB/MAC NAAT
Smear read and
reported in 24
hours TB or NTM ID:
MPT64Ag lat flow (TB)
MALDI/line-probe or
sequencing and
report ID
Laboratory Testing Algorithm - PHOL
MALDI-ToF: a type of Mass Spectrometry
• Matrix Assisted
• Laser Desorption/ Ionizing
• Time of Flight
• Mass Spectrometry
Your sample is co-crystallized with “matrix” keeps proteins intact, absorbs light
A pulse of laser light forces molecules into gas phase (desorption) and ionizes them
Ions “fly“ down a high-vacuum flight tube then strike the detector and the ToF is measured
Figure courtesy J. Kus, PHO
What is available for the Clinical Microbiology Lab Today?
• Bruker MALDI Biotyper– Microflex LT, FlexControl software– Bruker microorganism database– Class I Medical Device – Health
Canada; database RUO– CE Mark
• bioMeriéux VITEK MS– Shimadzu hardware with
microbial database acquired from AnagnosTec
– RUO database –SARAMIS– IVD database – MS-ID - Class I
Medical Device – Health Canada– CE Mark
Figure courtesy J. Kus, PHO
PublicHealthOntario.ca
Implementation of MALDI-ToF at PHOL
11
• First MALDI instrument - 2013:• Anaerobes – June 2013
• Phased in implementation of Gram-positive and Gram-negative organisms (e.g. enterococci, staphylococci, HACEK) from 2013 - 2016
• Enterobacteriaceae – May 2017
• Second MALDI instrument - 2016:• Purchased as back-up for first MALDI instrument and for additional
capacity
• Mycobacteria spp. - March 2017 (M. chimaera module Dec 2017)
• Yeast – 2016
• Nocardia/aerobic actinomycetes – 2017
• Additional organisms currently under evaluation (e.g. N. gonorrhoeae, moulds)
PublicHealthOntario.ca
Mycobacteriology MALDI Evaluation:Extraction Validation
12
• To determine optimal method for isolate identification in isolates from liquid media (MGIT 960)
• Method must provide an acceptable score > 1.8 in > 70% of isolates tested
• Evaluated 5 extraction methods: Bruker, Ottawa Hospital (courtesy of Dr. M. Desjardins), 3 modifications of Brukermethod
• Each method assessed using Type strains: 2 M. avium, 3 M. fortuitum, and 1 M. gordonae
• Final method (best scores obtained in all 6 isolates):• Modification of Bruker method utilizing an extra wash step and bead
beating
PublicHealthOntario.ca
MALDI-ToF for Mycobacteria spp Identification Evaluation:Summary of Protocol
13
• Test a representative sample size for each species based on the most common species encountered (min 5 – 10 common species; 1 – 3 rare, and non-mycobacteria)
• Isolates selected from fresh cultures, subcultures from frozen archived isolates (identified by Hain LPA; HPLC; 16S, hsp65, ITS sequencing), and Mycobacterium spp Type strains
• “Mixed cultures (2 organisms)” were run to assess MALDI performance
• Reproducibility testing within runs, between runs, day-to-day, and between users
• Sequencing was reference “gold standard” for discordant results arbitration
• Agreement to species > 90% (reportable scores > 1.79)
• Evaluation run from October 2016 – January 2017
• Post-implementation performance tracked over 6 months
14
Organism 2014 2015 Organism 2014 2015
M. abscessus 296 341 M. longobardum 0 2
M. agri 0 0 M. mageritense 8 3
M. arupense 1 5 M. malmoense 2 1
M. asiaticum 0 1 M. marinum 10 10
M. avium 4256 5900 M. mucogenicum 103 152
M. bohemicum 2 1 M. nebraskense 0 1
M. bovis 0 1 M. neoaurum 7 7
M. bovis BCG 17 8 M. nonchromogenicum 0 0
M. branderi 0 1 M. novocastrense 0 1
M. celatum 1 1 M. obuense 1 5
M. chelonae 106 91 M. palustre 0 0
M. cosmeticum 2 0 M. paraterrae 0 1
M. elephantis 0 3 M. peregrinum 22 26
M. flavescens 0 1 M. phlei 2 0
M. fortuitum 257 336 M. scrofulaceum 13 5
M. gilvum 3 0 M. senegalense 21 23
M. goodii 4 1 M. shimoidei 13 4
M. gordonae 747 838 M. simiae 20 14
M. heckeshornense 1 0 M. smegmatis 2 0
M. interjectum 3 5 M. szulgai 2 10
M. intermedium 0 0 M. triplex 0 1
M. intracellulare 525 552 M. triviale 1 0
M. iranicum 1 1 M. vaccae 1 0
M. kansasii 95 70 M. vulneris 0 0
M. kyorinense 0 0 M. wolinskyi 1 1
M. kubicae 0 2 M. xenopi 842 793
M. kumamotonense 8 11 M. tuberculosis 1556 1491
M. lentiflavum 77 140 TOTAL 9029 10861
PublicHealthOntario.ca
Type strain (ATCC, CIP)
n = 40
Line probe assay (Hain)
Solid media n = 193
n = 318
Sequencing (16S, hsp65 )
n = 71
HPLC
n = 14
n = 649
Type strain (ATCC, CIP)
n = 27
Line probe assay (Hain)
Liquid media n = 222
n = 331
Sequencing (16S, hsp65 )
n = 24
HPLC
n = 58
Isolates selected for MALDI validation
Number of clinical isolates by identification method
and Type strains
LJ
MGIT
PublicHealthOntario.ca
Precision Verification:
16
Mixed Cultures Evaluation:• 31 cultures with 2 organisms tested
• 5/31 (16.3%) had reportable scores and accurately identified both organism species
• 24/31 (51.6%) only 1 of the organisms present was accurately identified with a reportable score
DetailsNumber of isolates
includedResults
Reproducibility10 previously tested isolates were repeated,
different days10 100% concordance
Within Run10 previously tested isolates were repeated on
the same run10 100% concordance
Between Run10 previously tested isolates were repeated on 2
different runs10 100% concordance
Between Users10 previously tested isolates were repeated on 2
different runs, different users10 100% concordance
PublicHealthOntario.ca
Accuracy Verification:
17
Performance(Bruker MBT Compass
V4.1)
Total testedN=649
%Agreement
SolidN=318
%Agreement
LiquidN=331
% Agreement
Correct identification to species -all
(score > 1.79)580/645 90.2 289/315 91.7 291/330 88.2
Correct species identification
580/582 99.7 288/289 99.7 290/291 99.7
Score < 1.79 63 25 38
Incorrect species identification (score > 1.79)
2 1 1
Species not in library 2 1 1
Excluded (discrepancies not resolved)
4 3 1
PublicHealthOntario.ca 18
SpeciesMALDI (>1.79)
Validation%
MALDI (>1.79) Post -implementation
%
M. abscessus 37/40 92.5 194/212 91.5
M. avium 108/118 91.5 2090/2645 79.0
M. chelonae 16/20 80.0 44/57 77.2
M. fortuitum 30/31 96.8 157/172 91.3
M. gordonae 30/34 88.2 277/353 78.5
M. chimaera-intracellulare 67/71 94.4 * *
M. kansasii 14/14 100 26/30 86.7
M. lentiflavum 18/19 94.7 44/53 83.0
M. marinum 10/12 83.3 6/6 100.0
M. mucogenicum-phocaicum group 19/21 90.5 57/61 93.4
M. peregrinum 3/4 75.0 3/4 75.0
M. senegalense 13/13 100 11/11 100.0
M. simiae 8/8 100 8/9 88.9
M. xenopi 28/33 84.8 108/161 67.1
M. tuberculosis complex19/21 90.5 13/16 81.3
PublicHealthOntario.ca
M. chimaera-intracellulare Subtyping Module* Validation
19
Performance(*Bruker MBT Compass V5.0)
Total testedN=29
%Agreement
Correct identification to species/group -all (score > 1.79)
27/29 93.1
Correct species identification 26/26 100
Score < 1.79 0
Incorrect species identification (score > 1.79)
0
Failed to distinguish within M. chimaera-M. intracelluare group
4 (2 M. chimaera and 2 M. intracellulare)
• 29 isolates tested: 12 M. chimaera and 12 M. intracellulare (confirmed by sequencing)3 M. chimaera/intracellulare group (ID by MALDI) –no sequence consensus ID2 M. marseillense (confirmed by sequencing)
• Implemented December, 2017
Centrifuge @ 15000 rpm for 10 min
then re-suspend in 300 µl H2O
Laboratory Workflow for MALDI-TOF MS ID of Mycobacteria spp. from Culture (MGIT or LJ)
MGIT –
vacuum
growth in 1.2
ml
LJ – suspend ≥ 1
large colony in
300 µl H2O
Centrifuge @ 15000
rpm for 10 min, then
remove all liquid
Re-suspend in 500 µl H2O
then vortex* @ 3000rpm
for 1 min
Ensure no
clumps
remain!
Vortex* @
3000 rpm
for 1 min
Heat
inactivation 20
min @ 95 C
Add 900 µl EtOH then
vortex* @3000rpm
for 1 min
Centrifuge @
15000 rpm for
3 min
Decant
supernatant
Centrifuge @
15000 rpm
for 3 min
Remove residual
liquid with micro-
pipette
CL3
CL2
Place open tubes in pass-through
(will dry during this time)
Add 0.1 mm beads
= pellet size
Add 40 µl ACN and
40 µl formic acid
Load tubes in chilled
BeadRuptor adaptor
Bead beat at 3.1 m/sec
for 120 seconds
Centrifuge @ 14000
rpm for 5 min
Pipette 1 µl in
duplicate to target
Add matrix
with Galaxy
Run target on
MALDI instrument!
*Disruptor Genie
PublicHealthOntario.ca 21
MGIT or
LJ positive
AFB on
smear?Contaminated / repeat smear
Patient history and
smear consistent
with referable
organism?
Mixed? (Smear or
previous mixed culture)
Refer to previous
culture ID
Cording
present?
MPT-64
Positive?
Report
MALDI-
TOF
Good ID?
HAIN CM/AS Suspect
Mixed?
SequencingGood ID?
Report
Yes
Yes
Yes
Yes
Report
No
Yes
No No
Yes
Yes
Yes
No*
No
Yes
Positive Culture Identification Algorithm
Assess status of
other media
No
No
No
No
*do not sequence if suspect mixed
or no “genus” band observed
PublicHealthOntario.ca
MALDI-ToF: Cost Analysis: March 1st 2018-Feb 28th 2019
22
• Materials and labour included (MALDI, Hain GenoType Mycobacterium CM/AS, 16S sequencing)
• MALDI – 1 FTE, Hain CM/AS – 2 FTE
• 6501 isolates from culture
• 5516 identified by MALDI alone (84.8%)
• MALDI - $12.27 CAD/test
• Hain CM/AS - $48.12 CAD/test
• 16S sequencing - $125.00 CAD/test
• Savings differential: $35.85/test (MALDI over Hain)
• 1 FTE savings absorbed into other components of the ID algorithm, and number of isolates requiring sequencing decreased by 85%
PublicHealthOntario.ca
Observations, Lessons Learned and Pearls:“Mycobacterium malmoense” ID from LJ
23
PublicHealthOntario.ca
Observations, Lessons Learned and Pearls:M. avium and intermediate score (1.6 – 1.79)
24
PublicHealthOntario.ca
Observations, Lessons Learned and Pearls:MALDI “Mixed” Messages
25
• MALDI isn’t optimal for identifying “mixed” cultures, but can be useful if careful attention is paid to the “top ten” list:
• A top score (green) isn’t necessarily the correct ID - when the rest of the list is reviewed, a closely related 2nd species may appear several times below (e.g. M. fortuitum and M. senegalense) with the second isolate confirmed as the ID on repeat or by other ID method
• 6 or more appearances in the top 10 list (not good scores) of an organism indicates it is in the culture, and will often be identified with a good score on repeat
PublicHealthOntario.ca 26
PHOL TB and Mycobacteriology Laboratory 2019
Thank-you!!